Eli Lil­ly ax­es 163 Der­mi­ra staffers, shut­ters Men­lo Park site as it clos­es in around Dupix­ent ri­val le­brik­izum­ab

Eli Lil­ly made it clear when it shelled out $1.1 bil­lion for Der­mi­ra that le­brik­izum­ab is re­al­ly what it want­ed to buy. One year in, the phar­ma gi­ant is com­plet­ing its cleav­age of the rest.

Days af­ter un­veil­ing the sale of Qbexza — Der­mi­ra’s on­ly ap­proved prod­uct, a piece of cloth to block ex­ces­sive sweat­ing — Lil­ly re­vealed plans to close down the biotech’s Men­lo Park fa­cil­i­ty, putting 163 jobs on the chop­ping block. The San Fran­cis­co Busi­ness Times first re­port­ed on the WARN no­tice filed in ear­ly April.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER